| The Effect of Vegetarian Diet on Patients With Metabolic Associated Fatty Liver Disease (NCT05443581) | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 2022-07-01 |
| A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) (NCT05024032) | Eli Lilly and Company | 2021-09-01 |
| Validity and Reliability of Commercially Available Metabolic Carts (NCT04995211) | Pennington Biomedical Research Center | 2021-07-22 |
| The Effect of High vs. Moderate Protein Consumption on Human Health (NCT04156165) | University of Copenhagen | 2019-11-01 |
| Markers of Carnitine Acetyltransferase (CrAT) Protein Activity and Carnitine Availability (NCT03697928) | Maastricht University | 2019-03-12 |
| Prospective Evaluation of the Incidence of PICS (NCT03584399) | Indiana University | 2019-03-01 |
| Amino Acid Metabolism in Fed Surgical Critically Ill Patients (NCT03451968) | Rabin Medical Center | 2018-12-02 |
| Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity (NCT03661879) | Novo Nordisk A/S | 2018-09-12 |
| Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (NCT03548987) | Novo Nordisk A/S | 2018-06-04 |
| STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (NCT03548935) | Novo Nordisk A/S | 2018-06-04 |
| A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity (NCT03479892) | Novo Nordisk A/S | 2018-03-13 |
| Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity (NCT03308721) | Novo Nordisk A/S | 2017-10-16 |
| Awareness, Care and Treatment in Obesity Management (NCT03235102) | Novo Nordisk A/S | 2017-08-03 |
| Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin (NCT02963922) | Novo Nordisk A/S | 2017-02-06 |
| Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting (NCT02963935) | Novo Nordisk A/S | 2017-02-06 |
| Tight Caloric Control in the Cachectic Oncologic Patient (TiCaCONCO or CoCooN) (NCT03058107) | Universitair Ziekenhuis Brussel | 2017-02-01 |
| First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity (NCT03015207) | Novo Nordisk A/S | 2017-01-06 |
| Human Metabolic Dynamics at Rest and During Aerobic Exercise Under Normobaric Normoxic and Moderate Hypoxic Conditions (NCT03121885) | Benjamin Gollasch | 2017-01-01 |
| In-market Utilisation of Liraglutide Used for Weight Management in Europe (NCT02967757) | Novo Nordisk A/S | 2016-12-22 |
| Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight (NCT02958085) | Novo Nordisk A/S | 2016-11-04 |
| A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity. (NCT02941042) | Novo Nordisk A/S | 2016-10-10 |
| Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity (NCT02918279) | Novo Nordisk A/S | 2016-09-29 |
| Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity (NCT02870231) | Novo Nordisk A/S | 2016-08-18 |
| A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects. (NCT02717858) | Novo Nordisk A/S | 2016-03-16 |
| A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years (NCT02696148) | Novo Nordisk A/S | 2016-03-14 |
| Improving Glucose and Lipid Metabolism Through Caloric Restriction Using Diet or Surgery (CRUDOS) (NCT02988011) | Uppsala University | 2016-02-28 |
| Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome (NCT02527200) | Novo Nordisk A/S | 2015-11-09 |
| Awareness, Care & Treatment in Obesity Management (ACTION) Study (NCT03223493) | Novo Nordisk A/S | 2015-10-29 |
| A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects (NCT02568306) | Novo Nordisk A/S | 2015-10-05 |
| Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus (NCT02453711) | Novo Nordisk A/S | 2015-10-01 |
| Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects (NCT02300844) | Novo Nordisk A/S | 2014-12-01 |
| Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects (NCT02235961) | Novo Nordisk A/S | 2014-09-04 |
| Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors (NCT02207348) | Novo Nordisk A/S | 2014-08-01 |
| Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo (NCT02079870) | Novo Nordisk A/S | 2014-03-06 |
| A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years (NCT01789086) | Novo Nordisk A/S | 2013-02-01 |
| Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea (NCT01557166) | Novo Nordisk A/S | 2012-06-07 |
| Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes (NCT01272219) | Novo Nordisk A/S | 2011-06-01 |
| Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes (NCT01272232) | Novo Nordisk A/S | 2011-06-01 |
| The Biological Rhythm of Human Metabolite (NCT03669809) | Shandong Provincial Hospital | 2011-05-01 |
| A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers (NCT00978393) | Novo Nordisk A/S | 2009-09-16 |
| Metabolic and Functional Impact of Various Breakfast Models (NCT03240757) | Ospedale San Donato | 2009-07-14 |
| Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance (NCT00781937) | Novo Nordisk A/S | 2008-10-30 |
| Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese Volunteers (NCT00728455) | Novo Nordisk A/S | 2008-07-01 |
| Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers (NCT00665665) | Novo Nordisk A/S | 2007-11-01 |
| The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes (NCT00422058) | Novo Nordisk A/S | 2007-01-10 |